Trials / Recruiting
RecruitingNCT05833932
Suhexiang Pill for Acute Ischemic Stroke: A Registry Study
Suhexiang Pill for Acute Ischemic Stroke: A Prospective Registry Study of Real-world Data
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Dongzhimen Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.
Detailed description
Suhexiang Pill, a traditional Chinese patent medicine, is widely used in China for acute stroke. However, there is a lack of evidence of its efficacy and safety for acute ischemic stroke in real-world setting. This registry study will recruit 1000 patients who receive Suhexiang Pill treatment after acute ischemic stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Suhexiang Pill | Suhexiang Pill is an approved traditional Chinese patent medicine. |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2023-04-27
- Last updated
- 2024-06-11
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05833932. Inclusion in this directory is not an endorsement.